SciSparc (SPRC) EBITDA (2016 - 2022)

SciSparc (SPRC) posted EBITDA of $1.6 million for Q4 2022, down 10.99% sequentially from $1.8 million in Q3 2022.

SciSparc (SPRC) EBITDA (2016 - 2022) Analysis & Trends

SciSparc has reported EBITDA for 5 years, with the latest figure at $1.6 million in Q4 2022.

Quarterly EBITDA changed N/A year-over-year to $1.6 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $5.5 million (changed N/A YoY) and the FY2025 annual result came in at -$8.4 million, down 14.46% from the prior year.
EBITDA declined to $1.6 million in Q4 2022 per SPRC's latest filing, from $1.8 million in the prior quarter.
Over five years, EBITDA peaked at $2.1 million in Q1 2018 and troughed at -$12.8 million in Q4 2018.
A 3-year average of -$214750.0 and a median of $1.7 million in 2018 frame the typical range for EBITDA.
The sharpest annual moves came in 2018 and 2019: EBITDA soared 230.85% in 2018, then sank 88.06% in 2019.
Over 3 years, EBITDA stood at -$12.8 million in 2018, then surged by 101.54% to $197000.0 in 2019, then surged by 730.46% to $1.6 million in 2022.
According to Business Quant data, EBITDA over the past three periods registered $1.6 million, $1.8 million, and $197000.0 for Q4 2022, Q3 2022, and Q2 2019 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	1.25 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	1.29 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	493.00 Mn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-815.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	325.05 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	231.44 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-1.55 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	133.12 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-375.75 Mn
10	SciSparc	836,385.99	836,385.99	-	-

Download Data